BusinessNewsNow is an affiliate of Stock Profiler.US, LLC.
Sign up Today for Your Free Stock and Updated News Subscription at http://www.stockprofiler.us Companies who want to broadcast their progress are welcome to contact Stockprofiler.US, LLC at 603-621-9420.
-------------------------------------------
HealthSonix, Inc. (OTC: HSXI)
HealthSonix, Inc. closed at $0.135 Tuesday, trading 44,545 shares.
Company News- February 5, 2008: HealthSonix Launches www.ZingiberRx.com to increase on line presence
HealthSonix, Inc. (OTC: HSXI | news | PowerRating | PR Charts ) (FRANKFURT: H7S) announced yesterday that it has launched a dedicated web site for its ZingiberRx Joint and Muscle cream: www.zingiberRx.com ZingiberRx joint and muscle cream is fast acting, non-staining, fast absorbing, and deep penetrating. Unlike most over-the-counter topical ointments, ZingiberRx is not a counter-irritant and does not create a hot or a cold sensation when applied.
Medical research studies into the medicinal properties of various plants in the ginger (Zingiberaceae) family have isolated the Zingiber cassumunar and Zingiber officinale species for their anti-inflammatory, anti-allergic and pain relieving properties.
"The launch of this web site coincides with on going retail sampling and couponing programs being tested in major pharmacy chains." said Dieter Doederlein, Vice President Corporate Development of HealthSonix. "The response to this new pain relieving cream, the first of its kind with ginger, continues to be very positive. We continue being a best selling topical pain reliever at those locations. "
The Company is also launching a major online sales and marketing campaign with Google and Yahoo adwords and banner ads on websites that cater to the 50+ population segment: "This new marketing program has been designed to increase awareness and promote direct to consumer sales from our online store." added Doederlein.
About HealthSonix, Inc.
HealthSonix, Inc. (OTC: HSXI | news | PowerRating | PR Charts ) (FRANKFURT: H7S) is a publicly traded research oriented medical technology company that develops and markets medical devices and healthcare products for institutional and consumer use. The company's patent pending medical devices deliver sound pressure waves to the human body for relief of pain and other musculoskeletal conditions. The focus is on arthritis, athletic injuries and conditions where acute or chronic pain is the cardinal symptom.
More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.
-------------------------------------------
TorreyPines Therapeutics, Inc. (NASDAQ: TPTX)
TorreyPines Therapeutics, Inc. closed at $2.02 Tuesday, trading 4,500 shares.
Company News- February 5, 2008: Multiple Dose Clinical Trial of TorreyPines Therapeutics' Tezampanel Demonstrates Compound is Safe and Well-Tolerated
TorreyPines Therapeutics, Inc. (NASDAQ: TPTX | news | PowerRating | PR Charts ) announced yesterday that data from its multiple dose clinical trial of tezampanel, an antagonist of the AMPA and kainate subgroup of glutamate receptors, show that the product candidate is safe and well-tolerated in normal male and female subjects. These Phase I results support the company's continued development of tezampanel as a novel therapeutic for chronic pain and expand its potential therapeutic applications across a variety of persistent conditions in which activation of glutamate receptors initiates or sustains pathophysiological processes. These conditions include cancer pain and neuropathic pain, as well as non-pain conditions such as epilepsy, muscle spasticity and rigidity, and Parkinson's disease. A recently completed Phase IIb clinical trial of tezampanel in 306 patients with migraine met its primary endpoint for pain relief at two hours using a single 40 mg subcutaneous dose. In five previously conducted placebo-controlled, Phase II trials, an intravenous formulation of tezampanel demonstrated analgesic effect across all five studies using a variety of chronic pain models. The Phase I double-blind, placebo-controlled trial enrolled 30 healthy male and female subjects in sequential, dose-escalating cohorts. Subjects received once-daily subcutaneous injections of placebo or 40 mg, 70 mg or 100 mg of tezampanel for four consecutive days, approximating exposure under steady-state pharmacokinetic conditions. Overall, tezampanel was well-tolerated. There were no dose-limiting adverse events or discontinuations from the study and reported adverse events were generally mild and transient.
"This study is an important step forward in the clinical development of tezampanel. Our ability to safely deliver multiple doses of tezampanel means that we can now pursue virtually any indication that requires chronic dosing," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines Therapeutics. "There is an emerging appreciation of the pathological effects of increased AMPA and kainate receptor activation by glutamate. By blocking both receptors, tezampanel and its oral prodrug, NGX426, may represent a unique and effective approach to treat a variety of chronic pain as well as non-pain conditions." Tezampanel is the first AMPA/kainate antagonist to be studied in clinical trials for chronic pain. Both tezampanel and NGX426 represent a novel, non-opiod, non-vascular and non-serotonergic approach to treating multiple chronic pain conditions. Tezampanel and NGX426 are antagonists of a subgroup of glutamate receptors referred to as AMPA and kainate. These receptors are found in areas of the central and peripheral nervous system that are important for the transmission of pain. For example, during a migraine attack, levels of glutamate increase and activate these receptors, facilitating the transmission of pain impulses. Tezampanel, by blocking the binding of glutamate to these receptors, is believed to inhibit the transmission of pain signals that lead to migraine headaches. The blockade of similar receptors in other regions of the brain or spinal cord has been shown in animal models to attenuate pathophysiological processes such as the muscle spasticity and rigidity that occurs following stroke and spinal cord injury, or that may be associated with multiple sclerosis.
About TorreyPines Therapeutics
TorreyPines Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of small molecules. The company is developing versatile product candidates, each potentially capable of treating a number of different diseases and disorders, including chronic pain, muscle spasticity and rigidity, cognitive disorders and xerostomia, or dry mouth. Further information is available at http://www.torreypinestherapeutics.com.
-------------------------------------------
Oncothyreon Inc. (NASDAQ: ONTY)
Oncothyreon Inc. closed at $2.19 Tuesday, trading 73,600 shares.
Company News- February 5, 2008: Oncothyreon launches new corporate website
Oncothyreon Inc. (NASDAQ: ONTY | news | PowerRating | PR Charts ) (TSX: ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, announced yesterday the launch of its new corporate website at http://www.oncothyreon.com.
"We are excited about our new corporate identity and pleased to launch this updated website, which provides additional information about our product pipeline and new services for the investment community," said Robert L. Kirkman, M.D., President and CEO of Oncothyreon.
Email Alerts Those wishing to receive direct notification of Oncothyreon's news releases, webcasts, events and other information may register online at the Oncothyreon website by visiting the "News & Events" page under the "Email Alerts" tab. Please contact Oncothyreon's investor relations department at ir@oncothyreon.com with any questions about the new site.
About Oncothyreon
Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit http://www.oncothyreon.com.
-------------------------------------------
NeoStem, Inc. (Amex: NBS)
NeoStem, Inc. closed at $1.45 Tuesday, trading 31,800 shares.
Company News- February 5, 2008: NeoStem Announces NY State License for Adult Stem Cell Collection
NeoStem, Inc. (Amex: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced yesterday receipt of a provisional license for comprehensive tissue procurement services for the collection of adult stem cells from the New York State Department of Health for the ProHEALTH Care Associates, LLP stem cell collection facility. ProHEALTH Care Associates is a multi-specialty network of over 100 physicians serving over 500,000 patients located in Long Island. ProHEALTH has gained particular renown by becoming the official medical provider of major regional sports franchises and events including the NY JETS, the NY Islanders, and the US Open Tennis Championships. Robin Smith, MD MBA, NeoStem's Chairman and Chief Executive Officer stated: "The licensing of this facility is a milestone in our development. We have spent the past year signing agreements with collection centers and development groups to position us for revenue growth in 2008. We will now begin to benefit from our achievements. ProHEALTH is one of the largest and most prominent multi-specialty practices in the NY metropolitan region.
Dr. David Cooper, Chief Executive Officer of ProHEALTH, said: "This alliance is a testament to our commitment to provide our patients with the leading edge of medical technology. We believe NeoStem's proprietary methodology for collecting and storing autologous adult stem cells will give patients in our community the ability to take advantage of stem cell therapies offered today, as well as new therapies in development." Dr. Smith added: "We anticipate the opening of additional collection facilities in 2008 and we will continue to build out our nation-wide network of collection centers. We are executing on our business plan and promoting the health and welfare of those individuals who chose to donate their own stem cells and store them with us."
About ProHEALTH
ProHEALTH Care Associates, LLP is the largest multi-specialty practice in New York State, with over 100 physicians caring for over 500,000 patients. ProHEALTH Corp. manages the LLP, as well as the ProHEALTH Ambulatory Surgery Center, all located in Lake Success, N.Y.
About NeoStem, Inc.
NeoStem is managing a growing nationwide network of adult stem cell collection centers, enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also recently entered the research and development and therapeutic arenas, through the acquisition of a worldwide exclusive license to an early-stage technology to identify and isolate rare stem cells from adult human bone marrow, called VSELs (very small embryonic- like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells.
-------------------------------------------
Forest Laboratories, Inc. (NYSE: FRX)
Forest Laboratories, Inc. closed at $41.28 Tuesday, trading 4,714,900 shares.
Company News- February 5, 2008: Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
Forest Laboratories, Inc. (NYSE: FRX | news | PowerRating | PR Charts ) announced yesterday preliminary results of a Phase III study of memantine HCl (currently marketed as Namenda , a twice-daily immediate- release formulation) in a novel once-daily formulation. The study evaluated the efficacy, safety, and tolerability of an innovative, proprietary, 28 mg memantine extended-release, once-daily formulation compared to placebo in outpatients with moderate to severe Alzheimer's disease currently treated with a cholinesterase inhibitor. The results indicate that patients treated with memantine 28 mg extended-release formulation experienced statistically significant benefits in cognition and clinical global status compared to placebo. Additional data from the study are expected to be presented later in the year.
The recommended dose for Namenda is currently 10 mg two times a day (20 mg/day), or for patients with severe renal impairment 5 mg twice a day (10 mg/day). Patients in this study were titrated to 28 mg/day in a once-daily modified release formulation. Namenda is currently available in tablets or liquid form.
"The higher dosage and once-daily formulation will provide patients with the efficacy and tolerability expected from Namenda, in a more convenient once-daily form," said Ivan Gergel, M.D., Senior Vice President of Scientific Affairs at Forest Laboratories and President of the Forest Research Institute. "Based on the results of this study, Forest plans to pursue a new drug application for the memantine extended-release once-daily formulation."
About the Study
A randomized, double-blind, placebo-controlled trial of 677 outpatients taking a cholinesterase inhibitor was conducted in multiple centers in Argentina, Chile, Mexico, and the U.S. Patients in the 24-week study were randomly assigned to receive either 28 mg/day of memantine extended release or placebo. The primary endpoints evaluated were change from baseline on the Severe Impairment Battery (SIB) and the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) rating at week 24. The study showed statistically significant higher cognitive abilities, as measured by the SIB, and clinical global status, as measured by the CIBIC-Plus, in patients treated with memantine 28 mg extended release compared to those treated with placebo (p=0.001 for SIB and p=0.008 for CIBIC-Plus, both using the pre-defined last observation carried forward analyses). The study also showed that the once-daily memantine extended-release formulation was well tolerated. The most common adverse events occurring at a higher rate than placebo were dizziness, diarrhea and headache.
About Alzheimer's Disease Alzheimer's disease is a progressive disease of the brain and the most common type of dementia. Dementia is used to describe the progressive loss of cognitive, intellectual, or functional abilities. Published reports project that by 2050 more than 16 million people in the U.S. will have Alzheimer's disease. Currently, all Alzheimer's disease medications approved in the U.S. other than Namenda belong to a class of agents called cholinesterase inhibitors.
About Namenda
Namenda (memantine HCl) is the first in a class of medications with a unique mechanism of action that focuses on the glutamate pathway, a target for the treatment of Alzheimer's disease. Indicated for the treatment of moderate to severe Alzheimer's disease, the FDA approved Namenda in October 2003 based on three studies of Namenda used alone as monotherapy or in patients on a stable dose of donepezil. Namenda is contraindicated in patients with known hypersensitivity to memantine HCl or any excipients used in the formulation. The most common adverse events reported with Namenda (greater than or equal to 5% and higher than placebo) in placebo-controlled trials in patients with Alzheimer's disease were dizziness, confusion, headache, and constipation. In patients with severe renal impairment, dosage should be reduced.
About Forest Laboratories and Its Products
Forest Laboratories (http://www.frx.com) is a U.S.-based pharmaceutical company dedicated to identifying, developing, and delivering products that make a positive difference in peoples' lives. Forest Laboratories' growing product line includes Lexapro (escitalopram oxalate), an SSRI indicated for adults for the initial and maintenance treatment of major depressive disorder and generalized anxiety disorder; Namenda (memantine HCl), an N-methyl D-aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Campral
* (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation; and Bystolic (nebivolol), a beta-adrenergic receptor blocking agent indicated for the treatment of hypertension. In addition to our growing product line, Forest also co-promotes the Daiichi Sankyo, Inc. products Benicar
* (olmesartan medoxomil), an angiotensin receptor blocker; Benicar HCT
* (olmesartan medoxomil-hydrochlorothiazide), an angiotensin receptor blocker and diuretic combination product; and AZOR* (amlodipine and olmesartan medoxomil), a calcium channel blocker and angiotensin receptor blocker combination product, all indicated for the treatment of hypertension. Forest Laboratories markets Namenda (memantine HCl) in the United States under license from Merz Pharma GmbH & Co. KGaA of Germany.
*Azor is a trademark of Daiichi Sankyo, Inc.; Benicar and Benicar HCT are registered trademarks of Daiichi Sankyo, Inc.; and Campral is a registered trademark of Merck Sante s.a.s., subsidiary of Merck KGaA, Darmstadt, Germany.
-------------------------------------------
American Dental Partners, Inc. (NASDAQ: ADPI)
American Dental Partners, Inc. closed at $8.97 Tuesday, trading 133,600 shares.
Company News- February 4, 2008: American Dental Partners to Present at the 2008 UBS Global Healthcare Services Conference
American Dental Partners, Inc. (NASDAQ: ADPI | news | PowerRating | PR Charts ) announced Monday that Gregory A. Serrao, Chairman, President and Chief Executive Officer, and Breht T. Feigh, Executive Vice President, Chief Financial Officer and Treasurer, will present at the UBS Global Healthcare Services Conference in New York City on Monday, February 11, 2008, at 1:30 p.m. EST.
The presentation will be webcast live and will be available in the investor relations section of the Company's website at www.amdpi.com. An archived version of the presentation will also be available through the Company's website for seven days following the conference.
About American Dental Partners, Inc.
American Dental Partners is one of the nation's leading business partners to dental group practices. The Company is affiliated with 26 dental groups which have 261 dental facilities with approximately 2,301 operatories located in 18 states.
-------------------------------------------
The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BusinessNewsNow.US has not been compensated for services rendered; BusinessNewsNow.US is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers, go to http://www.businessnewsnow.us/ (disclaimers)
CONTACT: BusinessNewsNow.US e-mail: info@businessnewsnow.us/ WWW: http://www.businessnewsnow.us/
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
|
|
